According to a recent study, plaque psoriasis patients with lower blood monocyte counts at baseline achieved early response and better outcomes when treated with secukinumab.
Guselkumab shows significant scalp psoriasis clearance in skin of colour patients
According to a recent study, guselkumab has shown significant improvements in skin clearance, scalp itch, and patient-reported health-related quality of life in skin of colour patients with moderate-to-severe scalp psoriasis.
Study shows IL-23 inhibitors linked to lowest risk on paradoxical AD in PsO patients
According to a recent study, IL-23 inhibitors used to treat psoriasis patients are associated with the lowest risk of paradoxical atopic dermatitis (AD) compared to other biologics.
Study shows PsO patients with pruritis, sleep disturbances experience lower QoL in all domains
According to a recent study, psoriasis (PsO) patients with pruritis and related sleep disturbances showed a lower quality of life in all domains.
Researchers create new tool to predict psoriatic arthritis in psoriasis patients
Researchers developed a tool, called the Psoriatic Arthritis Risk Estimation Tool (PRESTO), using clinical variables to predict psoriatic arthritis (PsA) risk in psoriasis patients with reasonable accuracy.
Roflumilast shows efficacy in 95% of plaque psoriasis patients
According to a recent press release, roflumilast showed significant improvement in disease severity in 95% of plaque psoriasis patients by week 8.
Study suggests Covid-19 may be associated with increased incidence of psoriasis
According to a recent study, patients who have contracted Covid-19 may have a higher risk of developing psoriasis and other immune-mediated inflammatory diseases (IMID).
EADV 2023 Day 2 Morning: Late Breaking Psoriasis Presentations
Dr. Vimal Prajapati reports live from the 2023 EADV Congress in Berlin and discusses late breaker presentations around orally administered treatments for psoriasis
EADV 2023 Day 1 Morning: The Pathogenesis of Psoriasis
Dr. Mark Kirchhof reports live from the 2023 EADV Congress in Berlin and gives insights into the International Psoriasis Council presentations regarding the pathogenesis of psoriasis.
Study shows risankizumab is effective regardless of prior biologic treatment
According to a recent study, risankizumab is effective at achieving skin clearance in moderate-to-severe plaque psoriasis patients regardless of whether they have been treated with biologics previously.
HealthMinute.TV 